We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+19.78%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$251M
AUM Growth
+$35.9M
Cap. Flow
+$5.21M
Cap. Flow %
2.07%
Top 10 Hldgs %
49.32%
Holding
52
New
14
Increased
11
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
AFMD
Affimed
AFMD
+$5.67M
2
HROW icon
Harrow
HROW
+$4.22M
3
AXGN icon
Axogen
AXGN
+$3.66M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$3.26M
5
KYNB
Kyntra Bio
KYNB
+$3.11M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$8.49M
2
CMRX
Chimerix, Inc.
CMRX
+$5.01M
3
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$4.5M
4
KITE
Kite Pharma, Inc.
KITE
+$4.38M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$4.28M

Sector Composition

Rank Sector Weight
1 Healthcare 94.46%
2 Miscellaneous 5.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
26
MacroGenics
MGNX
$260M
$3.42M 1.36%
90,000
+40,000
+80% +$1.31M
INSY
27
DELISTED
Insys Therapeutics, Inc.
INSY
$3.2M 1.27%
89,000
-131,000
-60% -$4.08M
TTPH
28
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$3.08M 1.23%
3,250
-5,500
-63% -$4.5M
AVGR
29
DELISTED
Avinger, Inc. Common Stock
AVGR
$2.69M 1.07%
+2
New +$2.83M
AXDX
30
DELISTED
Accelerate Diagnostics
AXDX
$2.6M 1.03%
10,060
– –
XOMA
31
DELISTED
Xoma
XOMA
$2.52M 1%
+32,500
New +$2.34M
TENX icon
32
Tenax Therapeutics
TENX
$82M
$2.34M 0.93%
20
+1
+5% +$114K
CYTO
33
DELISTED
Altamira Therapeutics Ltd
CYTO
$1.73M 0.69%
+4
New +$1.66M
TNXP icon
34
Tonix Pharmaceuticals
TNXP
$233M
– –
0
– –
ZGNX
35
DELISTED
Zogenix, Inc.
ZGNX
$1.53M 0.61%
+114,063
New +$1.4M
INNL
36
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$1.48M 0.59%
+101,200
New +$1.12M
EVOK
37
DELISTED
Evoke Pharma
EVOK
$1.35M 0.54%
1,799
+98
+6% +$83.4K
CELGZ
38
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$950K 0.38%
456,492
-33,508
-7% -$85.8K
FOMX
39
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$871K 0.35%
+85,000
New +$939K
BLRX
40
BioLineRX
BLRX
$12.1M
$495K 0.2%
417
– –
AGRX
41
DELISTED
Agile Therapeutics
AGRX
$472K 0.19%
+28
New +$597K
NDRM
42
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$399K 0.16%
+26,000
New +$366K
DERM
43
DELISTED
Dermira, Inc.
DERM
$330K 0.13%
+18,800
New +$290K
AGIO icon
44
Agios Pharmaceuticals
AGIO
$2.05B
– –
-90,000
Closed -$8.49M
IOVA icon
45
Iovance Biotherapeutics
IOVA
$3.74B
– –
-200,000
Closed -$2.42M
NSPR icon
46
InspireMD
NSPR
$41.6M
– –
0
– -$400K
TCON
47
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
– –
-61
Closed -$171K
KITE
48
DELISTED
Kite Pharma, Inc.
KITE
– –
-76,000
Closed -$4.38M
BDSI
49
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-140,500
Closed -$1.48M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2015 Portfolio in Review

As of Q2 2015, Opaleye Management held 52 positions worth $251M, up 17% from $215M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Opaleye Management's Q2 2015 filing shows 14 new, 11 increased, 9 reduced and 5 closed positions. Its largest new stake was Affimed: 59,030 shares worth $7.95M. The largest sale was Agios Pharmaceuticals, an estimated $8.49M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q2 2015 buy was Affimed: 59,030 shares worth $7.95M.
  • Opaleye Management added most to Harrow in Q2 2015, an estimated $4.22M increase.
  • Opaleye Management's biggest Q2 2015 reduction was Chimerix, Inc., cutting an estimated $5.01M.
  • Opaleye Management fully exited Agios Pharmaceuticals in Q2 2015, selling an estimated $8.49M.
  • Opaleye Management's ten largest holdings make up 49% of its $251M portfolio in Q2 2015.
  • Opaleye Management opened 14 new positions and closed 5 in Q2 2015.
  • Opaleye Management's portfolio value rose 17% quarter-over-quarter to $251M.

Based on Opaleye Management's 13F filing for Q2 2015, filed 14 Aug 2015.